NCT06075004 Total Periarticular Infiltration Vs Posterior Periarticular Infiltration Plus PENG Block for Hip Analgesia
| NCT ID | NCT06075004 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chile |
| Condition | Hip Osteoarthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 74 participants |
| Start Date | 2023-10-18 |
| Primary Completion | 2025-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 74 participants in total. It began in 2023-10-18 with a primary completion date of 2025-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In a recent study, direct periarticular local anesthetic infiltration (PAI) showed a greater incidence of early quadriceps weakness (33% at 3 hours and 13% at 6 hours) than pericapsular nerve group block (PENGB) in total hip arthroplasty (THA) but, in turn, demonstrated a statistically significant better pain control. Additionally, PENGB could not completely circumvent motor compromise either, particularly at 3 hours (20% incidence), probably secondary to an injectate migration towards the femoral nerve. Posteriorly to this publication, a cadaveric trial looking into the maximum effective volume that spared the femoral nerve resulted in 13.2 mL. This newer evidence led to the design of a strategy that combines both interventions, aiming to obtain the best of them and have a solid alternative for those cases where very early mobilization is pursued. Thus, it is hypothesized that posterior PAI added to a low-volume PENGB (10mL) represents a superior alternative to PAI in terms of strength preservation and provides effective analgesia during the first 24 postoperative hours after THA.
Eligibility Criteria
Inclusion Criteria: * American Society of Anesthesiologists classification 1-3 * Body mass index between 20 and 35 (kg/m2) Exclusion Criteria: * Adults who are unable to give their own consent * Pre-existing neuropathy (assessed by history and physical examination) * Coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work-up i.e. platelets ≤ 100, International Normalized Ratio ≥ 1.4 or prothrombin time ≥ 50) * Renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work-up i.e. creatinine ≥ 100) * Hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work-up i.e. transaminases ≥ 100) * Allergy to local anesthetics (LAs) or morphine * Pregnancy * Prior surgery in the inguinal area corresponding surgical side * Chronic pain syndromes requiring opioid intake at home
Contact & Investigator
Daniela Bravo, MD
PRINCIPAL INVESTIGATOR
University of Chile
Frequently Asked Questions
Who can join the NCT06075004 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Hip Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06075004 currently recruiting?
Yes, NCT06075004 is actively recruiting participants. Contact the research team at dbravoadvis@uchile.cl for enrollment information.
Where is the NCT06075004 trial being conducted?
This trial is being conducted at Santiago, Chile.
Who is sponsoring the NCT06075004 clinical trial?
NCT06075004 is sponsored by University of Chile. The principal investigator is Daniela Bravo, MD at University of Chile. The trial plans to enroll 74 participants.